Weight-loss injections have become increasingly popular in the UK, with millions turning to these treatments as a means to combat obesity and improve health. However, users’ experiences vary widely, with some reporting significant benefits alongside concerning side effects.

Debra Smith, a 34-year-old from Darlington, Co Durham, began using the medication Mounjaro privately in early 2025 to address her weight struggles. Initially weighing 13 stone 7 pounds, she gradually increased her dosage to 12.5 mg, costing approximately £200 per month. Over eight months, she lost nearly four stone but began experiencing severe hair loss, with about 50 percent of her hair shedding over three months. Despite this, Smith resumed the treatment at a lower dose of 2.5 mg, stating that although losing her hair was distressing, she values the overall positive impact on her confidence and well-being. She emphasized the need for better warnings regarding potential side effects, particularly the link between rapid weight loss without adequate protein intake and hair loss.

Similarly, Laura and Lee Berry, a couple from Wythenshawe, Manchester, have credited weight-loss injections with transforming their health and personal lives. Since March 2026, Laura, aged 40, and her husband Lee, 42, have collectively lost nine stone. Laura has reduced from a UK dress size 24 to 14, using a 5 mg dosage of an unapproved compound similar to Retatrutide purchased online at £30 per month. Lee uses the GLP-1 inhibitor Tirzepatide (Mounjaro) at 5 mg, costing around £70 per month. Both reported no side effects and noted improvements in energy levels and intimacy. Laura described the treatment as a catalyst for changing her mindset about food, leading to healthier eating habits and increased physical activity such as running three times weekly.

The growing use of GLP-1 receptor agonists like semaglutide (marketed as Wegovy) and Tirzepatide reflects a broader trend since Wegovy’s NHS approval in September 2023. These drugs, injected weekly, have outperformed earlier daily treatments such as Saxenda in clinical trials, showing average weight loss of around 15 percent compared to 8 percent with prior medications. Despite this, NHS access remains limited to specialist clinics with lengthy waiting lists, pushing many to seek prescriptions through private providers. It is estimated that around 2.6 million people in the UK have used or are using weight-loss injections, with eight million more considering them.

While these treatments have shown promise in addressing obesity and reducing related health risks like heart disease and Type 2 diabetes, regulatory and safety concerns persist. The Medicines and Healthcare Products Regulatory Agency has recorded approximately 150,000 adverse reactions and 216 deaths linked to weight-loss drugs. Critiques highlight an unregulated market, with some users obtaining medications online without adequate medical supervision, raising the risk of misuse, particularly among vulnerable groups including individuals with eating disorders.

Experts including eating disorder specialist Elle Mace warn that easier access without proper monitoring may contribute to dangerous patterns and call for a return to stricter NHS-controlled distribution. Personal trainer Louis Mayers also cautions that these drugs can foster dependency and rebound weight gain once treatment stops, emphasizing the importance of sustainable lifestyle changes such as balanced nutrition and physical exercise over quick fixes.

Despite these debates, many users like the Berrys continue to advocate for the transformative benefits of weight-loss injections, praising their impact on quality of life and physical health. As demand grows, stakeholders face the challenge of balancing accessibility, safety, and effective regulation within this rapidly evolving sector.